Esomeprazole/naproxen

Drug Profile

Esomeprazole/naproxen

Alternative Names: Naproxen/esomeprazole; naproxen/esomeprazole magnesium; PN-400; Vimovo

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AstraZeneca; POZEN
  • Developer Aralez Pharmaceuticals Inc.; AstraZeneca
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 30 Mar 2017 Horizon Pharma receives patent allowance from USPTO for naproxen/esomeprazole
  • 20 Aug 2015 Horizon Pharma receives patent allowance for esomeprazole/naproxen in USA
  • 04 Feb 2015 POZEN and Horizon Pharma obtain additional patent protection for esomeprazole/naproxen in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top